Speakers and Participants:
Andrew J. Bauer, MD, pediatric endocrinologist and Medical Director of the Pediatric Thyroid Center
Theodore W. Laetsch, MD, pediatric oncologist and leader of the Developmental Therapeutics Program and the Very Rare Malignant Tumors Program
Sogol Mostoufi-Moab, MD, MSCE, pediatric oncologist and endocrinologist and leader of the Endocrine Late Effects after Cancer Therapy (ELECT) Program
Standard therapy for thyroid cancer in children involves surgical resection followed by radioactive iodine therapy in patients with invasive differentiated thyroid carcinoma. With the emergence of systemic chemotherapy as an option for care in adults patients, including tyrosine kinase inhibitors as well as oncogene-specific targeted therapy, there is an opportunity to incorporate these oral agents into clinical practice for pediatric patients with refractory, anatomically progressive disease after standard therapy has failed as well as an opportunity for a paradigm shift where medical therapy with prior to surgery (neoadjuvant therapy) may maintain low-disease specific mortality and optimize outcome by reducing treatment-associated complications for patients that present with morbidly invasive disease at diagnosis. This lecture will review if and when these medications may be considered in caring for pediatric patients with advanced thyroid cancer and explore very rare tumors and developmental and advanced pediatric thyroid cancer therapeutics.